Mycobacterium tuberculosis PPE2 protein-derived peptide ameliorates DSS-induced colitis by depleting mast cells Authors: Pooja Kushwaha, Sangita Mukhopadhyay Published: 2026 ABSTRACT SummaryIn the present study, we demonstrated that a synthetic peptide derived from the Mycobacterium tuberculosis PPE2 protein alleviates dextran sodium sulphate (DSS)-induced colitis in mice and markedly improves ulcerative colitis (UC) symptoms, as evidenced by improvement in body weight loss, disease activity index (DAI) score, colon length, and decrease in myeloperoxidase activity. PPE2-peptide treatment attenuated the induction of pro-inflammatory cytokines, enhanced the mRNA levels of tight junction proteins (Occludin, Claudin-1, and ZO-1), and prevented gut barrier function. PPE2 acts mainly by targeting the mast cells, as adoptive transfer of mast cells restored the symptoms of DSS-induced colitis in PPE2-treated mice. We further explored the development of a combination therapy aimed at targeting multiple pathways involved in inflammatory bowel disease (IBD) pathogenesis and showed that combination therapy of PPE2-peptide and mesalazine had better efficacy in improving UC symptoms. This study highlights a potential therapeutic strategy targeting fibroblast-mast cell crosstalk in IBD.Keywords: PPE2-peptide, ulcerative colitis, inflammation, fibroblast-mast cell, stem cell factor, therapeutic Introduction Inflammatory bowel disease (IBD), comprising Crohn’s disease (CD) and ulcerative colitis (UC), is a chronic inflammatory disorder of the gastrointestinal tract characterized by relapsing and remitting episodes of intestinal inflammation. The global prevalence of IBD has been rising, affecting millions worldwide, with increasing incidence in newly industrialized regions, suggesting a strong influence of environmental and immunological factors.1 The pathogenesis of IBD involves a complex interplay of genetic predisposition, dysregulated immune responses, gut microbiota alterations, and environmental triggers. Clinically, IBD manifests symptoms such as abdominal pain, diarrhea, weight loss, and fatigue, significantly impairing patient’s quality of life. Though evidence suggest a role of mast cells (MCs) in IBD pathology,2,3 their critical contribution to determining disease severity has not yet been firmly established. These immune cells, traditionally known for their involvement in allergic reactions, are increasingly recognized as key mediators of inflammation and tissue remodeling in the gut.4,5 Mast cells are densely populated in the intestinal mucosa and, upon activation, release a plethora of pro-inflammatory mediators, including histamine, cytokines, proteases, and leukotrienes, which contribute to epithelial barrier dysfunction, immune cell recruitment, and fibrosis.6 Their strategic location at the host-environment interface positions them as crucial regulators of gut homeostasis and inflammation.6 Dysregulated mast cell activity is thought to be responsible for exacerbating IBD progression, with studies demonstrating elevated mast cell numbers and activation states in inflamed intestinal tissues of patients with IBD.3 Furthermore, mast cell-derived mediators can modulate neuronal signaling, contributing to visceral hypersensitivity and pain,7 which are also hallmark features of IBD. Given their multifaceted role in immune modulation, barrier integrity, and neuroimmune interactions, mast cells probably represent a promising therapeutic target in IBD. The Mycobacterium tuberculosis (Mtb) protein PPE2, composed of 556 amino acids, has been shown to modulate the host immune responses. During Mtb infection, PPE2 is released from the bacterium and is translocated into the nucleus of macrophages, where it suppresses the production of nitric oxide (NO) by interacting with the GATA-1 binding site of the inducible nitric oxide synthase (iNOS) promoter.8 PPE2 also interferes with the generation of reactive oxygen species (ROSs) by disrupting the assembly of the NADPH oxidase complex.9 PPE2 has also been shown to suppress the mast cell population and its recruitment to the site of inflamed paw tissue in BALB/c mice, along with a reduction of pro-inflammatory cytokines such as interleukin (IL)-6 and tumor necrosis factor (TNF)-α.10 Importantly, a synthetic peptide derived from PPE2 was also found to suppress the mast cell population and inhibit pro-inflammatory cytokines in formalin-induced inflamed paw tissue.10 Therefore, we investigated whether the PPE2-derived peptide could provide protection in a dextran sulfate sodium (DSS)-induced colitis mouse model. In this study, we demonstrate that the administration of the PPE2-peptide significantly ameliorates DSS-induced colitis in mice. We observed an important role of mast cells in IBD pathology. The therapeutic effect of the peptide was found to be predominantly mediated through the selective depletion of mast cell populations and suppression of their inflammatory mediators in the colon tissue of colitis mice. Mechanistically, we established that PPE2-peptide exerts its anti-inflammatory effects by inhibiting the transcription of stem cell factor (SCF) in fibroblasts, thereby disrupting a critical signaling axis essential for mast cell survival, recruitment, and local proliferation. Given that fibroblast-derived SCF serves as a pivotal regulator of mast cell homeostasis via c-Kit (SCF-receptor) signaling,11 our findings highlight a fibroblast-mast cell crosstalk as a potential therapeutic target for IBD intervention. This approach holds significant translational potential, particularly for refractory IBD cases where current therapies fail to address mast cell-mediated pathology. A combination therapy of PPE2-peptide with mesalazine showed enhanced efficacy in ameliorating UC symptoms. Results PPE2-peptide attenuates the progression of DSS-induced UC Mast cells are known to release various mediators that contribute to inflammatory processes.12 Though mast cells are found in high numbers in gut mucosa, particularly at the lamina propria, not many studies have been carried out to understand the influence of mast cells in IBD pathogenesis. Since the pathogenesis of UC is strongly associated with an inflammatory milieu,2,13,14 it is possible that mast cells play an important role in regulating UC, and inhibition of mast cells could be a promising approach to reduce the inflammation of the gastrointestinal tract. We have shown earlier that a peptide derived from the PPE2 protein of M. tuberculosis reduces the mast cell population in inflamed paw tissue of mice.10 Therefore, in this study, we investigated the therapeutic potential of PPE2-peptide for the treatment of UC. PPE2 is a large protein (∼56 kDa) that contains a putative leucine zipper motif (KTLLEQTLALLPAALPLLAAPLAPLTL) and a nuclear localization signal (NLS, RRRRPKIKQ) at its C-terminal end. To enhance cellular delivery and minimize immunogenicity, a 36-amino acid PPE2-derived peptide (∼3.9 kDa) was designed by combining both the NLS and the DNA-binding domain, as previously described.10 A scrambled control peptide was generated by altering the DNA-binding region while retaining the NLS sequence (AETTPPALLPLLAQLLPAALAKLLLTLRRRRPKIKQ). We used a DSS-induced acute colitis mouse model that mimics the key features of UC in humans. Accordingly, C57BL/6 mice were given 3% DSS in drinking water ad libitum for 7 days to induce colitis. When mice were on DSS, PPE2-peptide (peptide) or scrambled peptide was administered intraperitoneally (dosage; 8 mg/kg on days 3, 5, 7, and 9) (Figure 1A). The dosage per mouse was decided based on previous findings.10 Mice receiving drinking water without DSS were used as a healthy control group. These mice were weighed and assessed daily for clinical markers of disease such as body weight, fur characteristics, stool consistency, and rectal bleeding, to obtain a disease activity index (DAI) score, according to the scoring criteria described in Table S1. As mice from the untreated DSS group were too weak to survive for longer days, we sacrificed mice from all groups at the end of day 9 for the analysis of disease biomarkers. Statistical analysis showed a significant reduction of body weight in the DSS-induced UC group compared to the healthy control group (Figure 1B). While the body weight was significantly improved upon PPE2-peptide treatment, it remained unchanged upon scrambled peptide treatment (Figure 1B). An increase in DAI was observed for the DSS-induced UC group compared to the healthy control group, which was expected (Figure 1C). Interestingly, PPE2-peptide treatment caused a decrease in DAI when compared with either the DSS-induced UC group left untreated or treated with scrambled peptide (Figure 1C). Further analysis through intragastrical delivery of fluorescein isothiocyanate (FITC)-dextran in mice demonstrated that intestinal permeability was significantly increased in the untreated DSS-induced UC group compared to the healthy control. Intestinal permeability was significantly reduced upon PPE2-peptide treatment, while scrambled peptide treatment did not have any rescue effect on DSS-induced intestinal permeability (Figure 1D). After sacrificing the mice at day 9, we also measured the colon length, as shortening of colon length due to edema, tissue injury, and muscle contraction is one of the clinical features to assess the UC pathophysiology. We observed that colon length was significantly reduced in the untreated DSS-induced UC group compared to healthy control, while colon length was increased significantly in mice treated with PPE2-peptide but not with scrambled peptide (Figures 1E and 1F). PPE2-peptide attenuates the progression of DSS-induced UC (A) An experimental scheme illustrates DSS-induced colitis in C57BL/6 mice and treatment with peptide. The acute colitis was induced by oral administration of 3% DSS in drinking water ad libitum for 7 consecutive days. When mice were on DSS, PPE2-peptide or scrambled peptide (8 mg/kg) was given intraperitoneally on days 3, 5, 7, and 9. Mice from the healthy control group were given normal drinking water. Mice from all the groups were sacrificed on day 9. (B) Mice body weights were recorded for each group every day, and percentage change in body weight was calculated. (C) Disease activity index (DAI) was calculated by considering respective scores for body weight loss, stool consistency, and rectal bleeding, respectively. (D) On the day of sacrifice (day 9), mice were deprived of food for 4 h. FITC-dextran (0.6 mg/kg body weight) was given intragastrically. After 3 h, mice were bled, and sera was collected. Fluorescence intensity was measured at excitation 488 nm and emission 520 nm. Serially diluted FITC-dextran in mouse sera was used to plot a standard curve. (E) Representative photograph of colon from each group after sacrificing the mice on day 9. (F) Quantification of colon length from each group. (G) At day 8, visceral pain was measured by evaluating the AWR score (0–4) in response to different colorectal distension volumes (50 μL, 100 μL, 150 μL and 200 μL). Data are presented as mean ± SEM of five mice per group for all experiments. Statistical analysis for B, C, and G was performed using two-way repeated-measures ANOVA. Statistical analysis for D and F was performed using an unpaired two-tailed Student’s t test. Given the importance of visceral pain in colitis, visceral sensitivity was assessed by measuring the abdominal withdrawal reflex (AWR; score 0–4) in response to colorectal distension in untreated and PPE2-peptide/scrambled peptide-treated DSS-induced colitis mice on day 8. The untreated DSS group showed significantly higher AWR scores compared to healthy controls at 200 μL, 150 μL, 100 μL and even at the lowest distension volume (50 μL), indicating enhanced visceral hypersensitivity during colitis (Figure 1G). In contrast, the PPE2-peptide treatment exhibited a significant decline in AWR score for similar distension volume compared to the untreated DSS group. The scrambled peptide group exhibited responses similar to the untreated DSS group, suggesting that the observed attenuation of visceral pain was specific to the PPE2-peptide (Figure 1G). These results indicate that PPE2-peptide treatment could rescue the clinical features of DSS-induced colitis in mice, and the DNA-binding region of PPE2-peptide is crucial for this therapeutic action. As genetic differences between strains, such as C57BL/6 (H2b) and BALB/c (H2d), and route of drug administration can influence immune responses, drug metabolism, and behavioral outcomes,15,16 similar experiments were conducted in BALB/c mice with the route of drug administration as intravenous. We observed similar results in BALB/c mice (Figures S1A–S1F), where PPE2-peptide treatment led to a significant amelioration of clinical symptoms. These data suggest that the effect of the peptide was robust across these experimental variables. To further test whether the PPE2-derived synthetic peptide (peptide) caused any hepatic or renal abnormality when administered for a longer duration, we injected C57BL/6 mice with either Phosphate buffer saline (PBS) or peptide (8 mg/kg) via intraperitoneal route for 10 continuous days. On day 11, mice were sacrificed, and sera were collected to check the levels of aspartate aminotransferase (AST or SGOT), alanine aminotransferase (ALT or SGPT), and alkaline phosphatase (ALP) as a measure of hepatic function, and the serum levels of creatinine, Blood urea nitrogen (BUN), urea, albumin, and total protein as a measure of renal function. The PBS and peptide-treated groups showed no differences in blood biochemical parameters (Figures S2A–S2H). Similarly, body weight (Figure S2I), stimulated activity, and fur appearance were also unaffected during peptide treatment. These findings suggest that the PPE2-derived synthetic peptide does not cause any hepatic and renal abnormalities when used for a longer duration, indicating that the peptide is safe for use as a therapeutic. PPE2-peptide mitigates inflammation and preserves barrier function in DSS-induced colitis As the cytokine network plays a central role in IBD pathogenesis, particularly UC, and is also critically associated with DSS-induced colitis,17 we further examined the level of pro-inflammatory cytokines such as IL-1β, IL-6, and TNF-α in colon tissue by real-time PCR (qPCR) and enzyme-linked immunosorbent assay (ELISA). A significant reduction at the transcript level (Figures 2A–2C) as well as at the protein level (Figures 2D–2F) of these cytokines was observed upon peptide treatment compared to the untreated DSS group. Although a significant reduction in serum level of IL-1β (Figure S3A) was observed in mice with DSS-induced UC that were treated with peptide when compared with the untreated group, no change in the anti-inflammatory cytokine (IL-10) was recorded (Figure S3B). Also, peptide-treated mice exhibited reduced colonic protein levels of IL-18 and IFN-γ and elevated IL-10 cytokine levels relative to untreated mice (Figures S3C–S3E). To further evaluate the extent of colonic inflammation, myeloperoxidase (MPO) levels were measured in colon tissues, as this enzyme is abundantly expressed in neutrophils, whose accumulation represents a hallmark of acute colonic inflammation. We observed a significant reduction in MPO activity upon peptide treatment in the DSS-induced colitis group compared to the untreated group (Figure 2G). These observations suggest that the peptide exerts anti-inflammatory effects in DSS-induced colonic inflammation. PPE2-peptide maintains intestinal permeability by suppressing inflammation Acute colitis was induced by oral administration of 3% DSS in drinking water ad libitum for 7 consecutive days. When mice were on DSS, PPE2-peptide (8 mg/kg) was given intraperitoneally on days 3, 5, 7, and 9. Mice from the healthy control group were given normal drinking water. Mice from all the groups were sacrificed on day 9, and the colon was harvested. (A–C) Colon tissues were used for RNA isolation, and real-time PCR was carried out to observe the transcript levels of pro-inflammatory cytokines: IL-1β (A), IL-6 (B), and TNF-α (C). Rps29 transcript level was used as an internal control. (D–F) Colon tissue lysates were used to measure protein levels of IL-1β (D), IL-6 (E), and TNF-α (F) by ELISA. (G) Colon tissue lysates were used to measure MPO activity, and absorbance was recorded at 460 nm. (H–K) RNA isolated from the colon tissue was used to measure the transcript levels of ZO -1 (H), Claudin-1 (I), Occludin (J), and Muc2 (K). (L) At day 9, after sacrificing the mice, the mid portion of the colon was harvested and stained with hematoxylin and eosin. A merged 4× overview image of the colon is shown, with selected regions enlarged at 10× (scale bars, 100 μm). Apical and basal regions from the 10× images were further magnified at 20× (scale bars, 20 μm). (M) Histopathological scores of the colons from various experimental groups were calculated by considering respective scores assigned to extent of inflammatory cell infiltration and colon architecture. Data are presented as mean ± SEM of five mice per group for all experiments. Statistical analysis for A–K and M was performed using an unpaired two-tailed Student’s t test. Several studies have reported that pro-inflammatory cytokines, such as TNF-α, IFN-γ, IL-1β, and IL-6, contribute to intestinal barrier dysfunction by downregulating the expression of key tight junction proteins, including zonula occludens-1 (ZO-1), claudin-1, and occludin.18,19,20,21 Therefore, we also compared the transcript levels of these tight junction proteins in various groups. The transcript levels of these core tight junction proteins were drastically decreased in the DSS-induced colitis group left untreated when compared with the healthy control, while their expression was significantly increased in mice treated with PPE2-peptide (Figures 2H–2J). Importantly, biopsy samples of patients with UC have revealed a thinner adherent mucus layer.22 The major structural component of the mucus layer is Mucin 2 (Muc2), and its synthesis and secretion are maintained by the goblet cells. As UC in humans and DSS-induced colitis are both associated with the depletion of goblet cells, we further measured the transcript level of Muc2 in all the groups. We found that the transcript level of Muc2 was drastically reduced in the untreated DSS group, while it was rescued upon peptide treatment (Figure 2K). Inflammation-associated colonic damage was further evaluated by histological analysis of H&E-stained sections. The healthy control group showed a normal array of mucosa, submucosa, and muscularis. Numerous goblet cells with vacuolated cytoplasm and thin lamina propria with few lymphocytes also appeared in the healthy control group. However, the sections of the DSS-group that were left untreated showed disturbed colon structure. Also, we observed complete loss of crypt structure, intense immune cell infiltration, mucosal ulceration, submucosal edema, and loose muscle fibers of muscularis in the DSS group. The presence of very few and shrunken goblet cells was also observed in this group. Importantly, sections from the peptide-treated group showed apparently normal colon lining structure and preserved crypts with many goblet cells, though a few infiltrated immune cells were still observed in the lamina propria (Figure 2L). The histopathology scores (Figure 2M), which were calculated based on inflammatory cell infiltration and colon architecture (Table S2), indicated that the DSS-treated group showed a significantly increased histological score, reflecting severe tissue damage, and inflammation. In contrast, the peptide-treated group had a marked reduction in the histological score, indicating considerable preservation of mucosal structure and reduced inflammatory response. Taken together, these observations indicate that the peptide could rescue the defective expression of these core tight junction proteins in DSS-treated mice, probably by subsiding the inflammation. PPE2-peptide improved hepatic and renal dysfunction in mice administered with DSS IBD is frequently associated with hepatic and renal dysfunction,23,24 as also observed in the DSS-induced colitis mice.25,26 To evaluate the potential protective effects of peptide therapy on kidney and liver function, blood samples were collected from all the groups at day 9 for the analysis of liver- and kidney-specific biochemical markers. Peptide administration caused a significant reduction of serum biomarkers associated with hepatic injury (AST, ALT, and ALP) and renal impairment (creatinine, blood urea, and BUN) in DSS-treated mice (Figure 3). These findings demonstrate that the peptide not only ameliorates intestinal inflammation but also probably mitigates DSS-induced systemic complications in the liver and kidneys. PPE2-peptide treatment reduces colitis-driven hepatic and renal pathological markers The acute colitis was induced by oral administration of 3% DSS in drinking water ad libitum for 7 consecutive days. When mice were on DSS, PPE2-peptide (8 mg/kg) was given intraperitoneally on days 3, 5, 7, and 9. Mice from the healthy control group were given normal drinking water. Blood was collected before sacrificing the mice from all the groups at day 9. (A–F) Hemolysis-free sera were used to analyze AST (A), ALT (B), ALP (C), creatinine (D), BUN (E), and blood urea (F). Data are presented as mean ± SEM of five mice per group for all experiments. Statistical analysis was performed using an unpaired two-tailed Student’s t test. PPE2-peptide reduces inflammation by targeting the mast cells in the inflamed colon of mice with acute colitis In healthy conditions, interaction among mast cells, intestinal epithelial cells, and gut microbes ensures the proper functioning of the intestinal barrier. During colitis, increased paracellular space and reduced mucus layer allow the interaction between mast cells and gut microbes. Upon activation, mast cells secrete various immunomodulators such as chymase and MMP9 that further increase the paracellular space and pro-inflammatory cytokines, which sustain the inflammation.6 Biopsy of a colon section of an active UC patient also shows the presence of mast cells in the mucosa.3 Notably, a study has shown that mast cell-deficient rats exhibit some resistance to DSS-induced colitis, emphasizing a probable role of mast cells in IBD pathogenesis.2 Earlier, it was shown that PPE2 protein reduces the mast cell population in a mouse model of mycobacterial infection27 as well as in inflamed paw tissue of mice.10 Since PPE2-derived peptide inhibits colonic inflammation in DSS-induced colitis, we next investigated the mast cell population in DSS-administered mice upon peptide treatment. On day 9, after sacrificing the mice, the colon was harvested, fixed, stained with toluidine blue, and the mast cell population was counted in colon sections from all the groups. We observed a significant increase in mast cells in the colonic mucosa of the untreated DSS group compared to the healthy control, while it was significantly decreased in colon tissue upon peptide treatment compared to untreated DSS-induced colitis mice (Figures 4A–4C). Further, we validated the mast cell parameter by flow cytometry. Single-cell suspension was prepared from colon tissue and analyzed through flow cytometry for the mast cell population (CD117+, FcεRΙ+). This analysis revealed a significant reduction in the mast cell population in the colon tissue of the peptide-treated DSS group compared to the untreated DSS group (Figure 4D and 4E). This observation corroborates our histological observation of mast cells in the colon section. PPE2-peptide reduces mast cells in the inflamed colon of acute colitis mice (A) Acute colitis was induced by oral administration of 3% DSS in drinking water ad libitum for 7 consecutive days. When mice were on DSS, PPE2-peptide (8 mg/kg) was given intraperitoneally on days 3, 5, 7, and 9. Mice from the healthy control group were given normal drinking water. At day 9, after sacrificing the mice, the mid portion of the colon was harvested and fixed. The colon tissue sections were prepared and stained with toluidine blue. Images were visualized at 20× (scale bars, 50 μm). (B and C) Quantification of mast cells in apical (B) and basal (C) parts of the colon in toluidine blue-stained sections was performed using ImageJ software and was normalized per unit area (mm2). (D) In another experiment, acute colitis was induced by oral administration of 3% DSS in drinking water ad libitum for 7 consecutive days. When mice were on DSS, PPE2-peptide (8 mg/kg) was given intraperitoneally on days 3, 5, 7, and 9. Mice from the healthy control group were given normal drinking water. At day 9, mice were sacrificed, and the entire colon was removed and used to prepare a single-cell suspension. Flow cytometry analysis was performed to analyze mast cell populations using anti-CD117 Ab and anti-FcεRIα Ab. (E) The percentage of mast cells in the colon tissues across all experimental groups was quantified using flow cytometry. (F) Colon tissue lysates were used to quantitate β-hexosaminidase activity. (G) Same colon tissue lysates were used to measure histamine levels by ELISA. (H and I) RNA isolated from the colon tissues was used to measure the transcript levels of MCP-3 (H) and mcpt4 (I) by real-time PCR. Data are presented as mean ± SEM of five mice per group for all experiments. Statistical analysis for B, C and E–I was performed using an unpaired two-tailed Student’s t test. Upon activation through damage-associated molecular patterns (DAMPs) and pathogen-associated molecular patterns (PAMPs), mast cell degranulates, and secrete various immunomodulators in tissue microenvironment such as pre-stored molecules such as histamine, serotonin, chemokines MCP-3 (CCL7), β-hexosaminidase, and mast cell proteases such as Mcpt4, as well as newly synthesized molecules such as MCP-1, TNF-α, IL-6, and IL-1β.12 Since we observed that peptide treatment depletes the mast cell population in the inflamed colon, we next measured the levels of mast cell signatures such as β-hexosaminidase, histamine, MCP-3, and Mcpt4 in these tissues. We observed that the colon tissue from the peptide-treated group showed a significant reduction in β-hexosaminidase activity (Figure 4F) and histamine levels (Figure 4G) when compared with colon tissue harvested from DSS-administered mice left untreated. The transcript levels of MCP-3 and mcpt4 were also significantly decreased in the DSS group upon peptide treatment compared to the DSS group left untreated (Figures 4H and 4I). These results indicate that peptide treatment reduced the level of mast cells and therefore the mast cell-associated inflammatory mediators in the DSS-induced inflamed colon. To validate the fact that PPE2-peptide reduced colonic inflammation in mice with DSS-induced colitis specifically through mast cell inhibition, we performed adoptive transfer of mast cells. For this, bone marrow-derived mast cells (BMMCs) were generated by differentiating bone marrow progenitors in vitro, and purity was confirmed by flow cytometry (∼80%) (Figure 5A). Approximately 1 × 106 BMMCs were transplanted intraperitoneally in DSS-induced colitis mice treated with PPE2-peptide, twice, on day 5 and day 7, and these mice were compared for various inflammatory parameters with the peptide-treated DSS-induced colitis mice that did not receive any adoptively transferred mast cells. We observed that adoptive transfer of mast cells reinstates the colitis-associated pathophysiology, as this group showed reduced body weight, increased DAI, and shortening of colon length almost similar to DSS-induced colitis mice left untreated (Figures 5B–5F). It appears that the protective efficacy of the PPE2-peptide against DSS-induced colitis was apparently overcome by local injection of BMMCs. As expected, the adoptive transfer of mast cells to peptide-treated colitis mice resulted in marked increase in MPO (Figure 5G) and β-hexosaminidase activity (Figure 5H), histamine levels (Figure 5I), as well as elevated level of pro-inflammatory cytokines including IL-1β (Figure 5J), IL-6 (Figure 5K) and TNF-α (Figure 5L) when compared with peptide-treated colitis mice that did not receive any exogenous mast cells. Similar to the DSS group, all mice in the BMMC-transplanted group died by day 10 even though they received the PPE2-peptide (Figure 5M), whereas no death was recorded for PPE2-peptide-treated colitis mice (Figure 5M). Taken together, these results establish the fact that peptide-mediated suppression of colonic inflammation occurs via selective targeting of mast cells. Intraperitoneal administration of mast cells restores colitis pathology in mice (A) Mast cells were enriched in the presence of SCF and IL-3 from the bone marrow of C57BL/6 mice of 6–8 weeks old, and the purity was confirmed by flow cytometry. Acute colitis was induced by oral administration of 3% DSS in drinking water ad libitum for 7 consecutive days. When mice were on DSS, PPE2-peptide (8 mg/kg) was given intraperitoneally on days 3, 5, 7, and 9. Mice from healthy control group was given normal drinking water. When mice were on DSS, about 1 × 106 cultured mast cells were intraperitoneally transplanted in the PPE2-peptide-treated group on days 5 and 7. (B) Percentage body weight was calculated on each day for all the groups. (C) Disease activity index (DAI) was calculated by taking the average of the assigned score for body weight loss, stool consistency, and rectal bleeding. (D) On the day of mice sacrifice (day 9), mice were deprived of food for 4 h and FITC-dextran (0.6 mg/kg body weight) was given intragastrically. After 3 h, mice were bled, and hemolysis-free sera were collected. Fluorescence intensity was measured at excitation 488 nm and emission 520 nm. Serially diluted FITC-dextran in mouse sera was used to plot the standard curve. (E) Representative photographs of the colon from each group after sacrificing the mice on day 9. (F) Quantification of colon length from each group. (G) Colon tissue lysates were used to measure the MPO activity, and absorbance was recorded at 460 nm. Serially diluted human leukocyte MPO was used to plot a standard curve. (H) Colon tissue lysates were used to measure β-hexosaminidase activity. (I–L) Colon tissue lysates were also used to measure the protein levels of histamine (I), IL-1β (J), IL-6 (K), and TNF-α (L) by ELISA. (M) Probability of survival graph was plotted for all the groups till day 10. Data are presented as mean ± SEM of five mice per group for all experiments. Statistical analysis for B and C was performed using two-way repeated-measures ANOVA. Statistical analysis for D and E–L was performed using an unpaired two-tailed Student’s t test. Survival analysis for M was conducted using the log rank (Mantel-Cox) test. To further investigate whether the PPE2 peptide directly affects mast cell viability, degranulation, and cytokines release, we have used the RBL-2H3 mast cell line and stimulated with lipopolysaccharide (LPS) (1 μg/mL) for 1 h28 and treated with different concentrations of PPE2-peptide for another 3 h. Cells were next harvested, stained with toluidine blue, and analyzed. We observed that LPS-induced mast cell degranulation remained unchanged across varying concentrations of PPE2-peptide (Figure S4A). Also, no significant changes were observed in β-hexosaminidase activity or histamine release upon LPS-stimulated degranulation of RBL-2H3 in the cultured medium either at 3 h or at 24 h of peptide treatment (Figures S4B–S4E). Similarly, transcript levels of MCP-3, mcpt4, and the pro-inflammatory cytokines IL-1β, IL-6, and TNF-α remained unaltered between the peptide-treated and untreated groups (Figures S4F–S4J). Moreover, in vitro assessment of cell viability by 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium (MTS) assay (Figure S4K) and flow cytometry based live/dead staining (Figure S4L) confirmed no cytotoxic effect of the peptide on mast cells. Taken together, these findings indicate that the peptide neither directly activates mast cells nor exerts any cytotoxic activity. PPE2-peptide targets the SCF promoter to attenuate mast cell population Since the observed reduction of mast cell population in the inflamed colon of mice did not appear to be due to a direct effect of the PPE2-peptide on mast cells, we hypothesized that the peptide probably reduced mast cell population indirectly by altering the local microenvironment. To validate this, we first looked for the physical presence and localization of the PPE2-peptide upon intraperitoneal administration in mice. After 1.5 h of peptide treatment, colon tissues were harvested and stained with an in-house-generated anti-PPE2 antibody that is capable of recognizing PPE2-peptide (Figure 6A). Immunofluorescence analysis by confocal microscopy revealed the widespread distribution of peptide across all colonic layers (Figure 6B). The peptide was found to be localized to the nucleus of a few cells present in the lamina propria and submucosa region of the colon, which are also the anatomical location of fibroblasts.29,30,31 Tissue-resident fibroblasts are a primary source of SCF.11 Previous studies have demonstrated elevated SCF expression in inflamed intestinal mucosal tissue, where it functions as a pro-inflammatory mediator.32,33 Neutralization of SCF has been shown to reduce colonic inflammation in DSS-induced colitis.34 Moreover, given that the interaction of SCF with SCF receptor (c-Kit) present on mast cell surface is very crucial for survival, local proliferation, and migration of mast cells from peripheral blood to the tissue,11 we speculated that PPE2-peptide may modulate mast cell population by altering the fibroblast-derived SCF expression. To test this, we quantified the SCF level in peptide-treated colitis colon tissue. We observed that the transcript level of SCF was significantly reduced upon peptide treatment compared to the untreated DSS-induced colitis group (Figure 6C). Since SCF in the colon is predominantly produced and secreted by fibroblasts, we first assessed the intracellular localization of the peptide in these cells. Accordingly, NIH-3T3 fibroblast cells were treated with PPE2-peptide for 2 h and observed that the peptide was translocated to the nucleus of NIH-3T3 fibroblasts (Figures 6D and 6E). To further validate whether PPE2-peptide inhibits SCF expression in fibroblasts, we performed in vitro experiments, where NIH-3T3 cells were stimulated with LPS for 30 min and treated with different concentrations of PPE2-peptide (125 nM, 250 nM, 500 nM, 1 μM) for another 3 h, and the transcript level of SCF was examined. Quantitative analysis revealed that the peptide inhibits SCF transcription in LPS-stimulated NIH-3T3 cells (Figure 6F). We observed significant reduction of SCF transcription at 250 nM and maximal suppression at 500 nM and 1 μM, suggesting that the peptide reaches its saturation concentration at ≥500 nM under these experimental conditions (Figure 6F). These findings demonstrate that the peptide inhibits SCF induction in fibroblasts. PPE2-peptide reducing mast cell population by downregulating the SCF transcript level (A) Affinity of in-house generated antibody against full-length PPE2 was evaluated against PPE2-peptide by western blotting. (B) C57BL/6 mice were intraperitoneally injected with PPE2-peptide. After 1.5 h of drug administration, mice were sacrificed and colon tissues were harvested, fixed, and immunofluorescence for PPE2-peptide was performed using in-house-generated anti-PPE2 antibody. Sections were imaged using a confocal microscope. Nuclei were stained with DAPI (scale bars, 50 μm). (C) Acute colitis was induced by oral administration of 3% DSS with drinking water ad libitum for 7 consecutive days. When mice were on DSS, PPE2-peptide was given intraperitoneally on day 3, day 5, day 7, and day 9. Mice from healthy control group was given normal drinking water. At day 9, after sacrificing the mice, colon tissues were harvested. RNA was isolated and the transcript level of SCF was examined by real-time PCR in all the groups. (D and E) NIH-3T3 cells were treated with PPE2-peptide for 2 h. After treatment, cells were fixed, permeabilized, and stained with in-house-generated anti-PPE2 antibody. DAPI was used to stain the nucleus (scale bars, 20 μm) (D). Nuclear localization of PPE2-peptide was measured by calculating Pearson’s correlation coefficient (E). (F) NIH-3T3 cells were stimulated with LPS for 30 min, then treated with different concentrations of PPE2-peptide for another 3 h. Cells were harvested to isolate RNA, and the transcript level of SCF was measured by real-time PCR. (G and H) NIH-3T3 cells were co-transfected with pGL3-SCF and pEGFP. The control group received the pGL3 empty vector alone. After 24 h of transfection, cells were treated with PPE2-peptide for 3 h. Cells were next harvested and analyzed for luciferase activity (G). Lysate prepared from the same sample was used to analyze GFP expression by western blotting using an anti-GFP antibody. β-actin was used as a loading control (H). (I) NIH-3T3 cells were treated with different concentrations of PPE2-peptide for 4 h, and an MTS assay was performed. Absorbance was recorded at 490 nm. Data are presented as mean ± SEM of five mice per group for C, 80 cells for E, and three independent experiments for F, G, and I. Statistical analysis for C, E, F, G, and I was performed using an unpaired two-tailed Student’s t test. PPE2 was shown to contain a leucine zipper DNA-binding domain and a NLS.8 Further, earlier studies have demonstrated that PPE2 protein was translocated into the nucleus of fibroblasts, where it binds to the 200 bp (−100 bp, +100 bp) of the core promoter region of SCF and represses its transcriptional activity.10 Given these findings and the fact that the PPE2-peptide was designed to have both leucine zipper motif and NLS domain, we hypothesized that the peptide might similarly bind to the SCF promoter to suppress SCF gene transcription. To test this, we performed a luciferase reporter assay where the putative promoter fragment of 200 bp (−100 bp, +100 bp) of SCF was cloned into a promoter-less vector, pGL3 (pGL3-SCF), as described earlier.10 Next, NIH-3T3 fibroblast cells were co-transfected with the pGL3-SCF construct and pEGFP vector, and the control group received the pGL3 basic vector alone. Twenty-four hours post-transfection, cells were treated with either PBS (vehicle control) or peptide at varying concentrations (250 nM, 500 nM and 1 μM), and following 3 h of peptide treatment, cells were harvested, and analyzed for luciferase activity. We observed a concentration-dependent decrease in luciferase activity in peptide-treated groups compared to the PBS control (Figure 6G). This reduction in promoter activity was correlated with the observed dose-dependent downregulation of SCF mRNA expression following peptide treatment (Figure 6F). Western blot analysis of Green fluorescent protein (GFP) expression in cell lysate using anti-GFP antibody confirmed consistent transfection efficiency across all treatment groups (Figure 6H). MTS viability assay confirmed that the peptide exhibited no cytotoxicity to NIH-3T3 fibroblasts at the tested concentrations (Figure 6I). These observations demonstrate that the decreased luciferase activity resulted specifically from the suppression of SCF promoter activity by the PPE2-peptide rather than compromised cell viability. In contrast, treatment with scrambled peptide did not alter luciferase activity, indicating that the scrambled sequence lacks functional transcriptional repressor activity (Figures S5A and S5B), though immunofluorescence staining demonstrated that the scrambled peptide is able to translocate into the nucleus of NIH3T3cells due to an intact NLS domain (Figures S5C and S5D). Additionally, in DSS-induced colitis mice, treatment with PPE2-peptide led to a significant reduction in SCF transcript levels compared to the DSS group, whereas scrambled peptide treatment showed no significant reduction (Figure S5E), thereby confirming the specificity of PPE2-peptide in suppressing SCF transcription. These studies together support direct transcriptional regulation of SCF by the PPE2-peptide in DSS-induced colitis. Peptide and mesalazine combination therapy enhances protective efficacy in DSS-induced colitis IBD is a complex and heterogeneous condition driven by immune dysregulation, microbial dysbiosis, epithelial barrier dysfunction, and genetic susceptibility. Given its multifactorial nature, monotherapies such as aminosalicylate derivatives, anti-TNF agents, Janus Kinase (JAK) inhibitors, or IL-12/IL-23 inhibitors often fail to maintain remission in a significant proportion of patients due to primary non-response, secondary loss of efficacy, or mechanistic escape.35 Even a subset of patients may develop resistance to these drugs over time.36 This underscores the need for combination therapy, which targets multiple pathogenic pathways simultaneously to enhance efficacy and durability. For this study, we selected mesalazine (MSZ), an aminosalicylate derivative and first-line therapy for both UC and CD.37 Unlike potent immunosuppressants, MSZ exerts localized anti-inflammatory effects in the gut by inhibiting NF-κB, prostaglandins, and oxidative stress without significant systemic immunosuppression,38 making it a preferable adjunct to biologics or small molecules in mild to moderate IBD. However, long-term or high-dose MSZ use is often linked to adverse effects such as kidney damage, liver toxicity, blood disorders, and male infertility.39 To mitigate these risks while maintaining efficacy, we reduced MSZ dosage and combined it with PPE2-peptide, aiming to enhance therapeutic outcomes compared to monotherapy by targeting multiple pathogenic pathways. The previously reported therapeutic concentration of MSZ in the range of 75–200 mg/kg40,41,42 has shown therapeutic efficacy in DSS-induced colitis mice. To minimize the side effects associated with long-term use, we evaluated a lower dose of 25 mg/kg, administered either alone or in combination with PPE2-peptide (8 mg/kg), under two regimens, alternate-day and daily dosing. It could be observed that at this lower dose, MSZ alone did not exhibit any protective effect when administered either on alternate days or daily, as mice showed similar body weight loss, DAI scores, and colon shortening when compared with the untreated DSS-induced colitis group (Figure S6). When combined with PPE2-peptide, no synergistic effect was observed, as the PPE2-peptide alone or its combination with MSZ at 25 mg/kg exerted similar therapeutic effects (Figure S6). Further, it was recorded that daily administration of PPE2-peptide along with MSZ at 25 mg/kg did not show any additional therapeutic benefit over the alternate dosage regimen (Figure S6). Therefore, we next evaluated MSZ at 50 mg/kg to assess its therapeutic efficacy in combination with the PPE2-peptide. Accordingly, mice were administered 3% DSS ad libitum in drinking water to induce colitis. MSZ (50 mg/kg, intragastric) and PPE2-peptide (8 mg/kg, intraperitoneal) were administered either as standalone or in combination on alternate days (Figure 7A). MSZ monotherapy demonstrated significant improvements in body weight (Figure 7B) and DAI (Figure 7C), though no notable difference in colon length was observed compared to the DSS control group (Figures 7D and 7E). Additionally, as expected, MSZ treatment reduced MPO activity (Figure 7F) and histamine levels (Figure 7H), along with a modest decrease in β-hexosaminidase activity (Figure 7G). Also, a significant downregulation of pro-inflammatory cytokines (IL-1β, IL-6, and TNF-α) was observed in the MSZ-treated group (Figures 7I–7K). Though PPE2-peptide treatment alone was effective, the combination of peptide and MSZ exhibited better efficacy compared to monotherapy with either MSZ or the peptide in reducing the colitis symptoms (Figures 7B–7K). The combined treatment significantly ameliorated loss of body weight, DAI, and colon shortening, while further suppressing MPO activity and mast cell-associated markers, including β-hexosaminidase activity and histamine, to a greater extent than individual treatment (Figures 7B–7H). Pro-inflammatory cytokines (IL-1β, IL-6, and TNF-α) were also markedly reduced in the combination group (Figures 7I–7K). In another set of experiments, these groups were left undisturbed for 30 days to assess survival of the mice. In the untreated DSS group, mice began to die by day 9, with complete mortality by day 12. MSZ-treated mice showed delayed mortality beginning on day 13, with a 40% survival rate by day 30. Remarkably, treatment with the peptide alone or in combination with MSZ resulted in 100% survival by the end of the 30-day observation period (Figure 7L). All these findings together suggest that the peptide-MSZ combination exerts enhanced therapeutic effects compared to MSZ monotherapy at a reduced dosage concentration of 50 mg/kg, highlighting its potential as a more effective strategy for mitigating DSS-induced colitis. The combination of PPE2-peptide and MSZ shows better efficacy than monotherapy (A) An experimental scheme illustrating DSS-induced colitis in C57BL/6 mice and treatment with PPE2-peptide/mesalazine (MSZ)/PPE2-peptide + MSZ. The acute colitis was induced by oral administration of 3% DSS with drinking water ad libitum for 7 consecutive days. When mice were on DSS, PPE2-peptide was given intraperitoneally while MSZ was given intragastrically as a standalone or in combination with PPE2-peptide on day 3, day 5, day 7, and day 9. Mice from healthy control group was given normal drinking water. Mice from all the groups were sacrificed on day 9. (B) Percentage body weight change on each day for all the groups. (C) Disease activity index (DAI) was calculated by taking the average of the assigned score for body weight loss, stool consistency, and rectal bleeding. (D) Representative photographs of colon from each group after sacrificing the mice on day 9. (E) Quantification of colon length from each group. (F) After sacrificing the mice on day 9, colon tissue lysates were prepared and used to measure MPO activity, and absorbance was measured at 460 nm. Serially diluted human leukocyte MPO was used to plot a standard curve. (G) β-hexosaminidase activity was also measured in colon tissue lysate. Absorbance was recorded at 405 nm. (H–K) Colon tissue lysates were used to measure the protein levels of histamine (H), IL-1β (I), IL-6 (J), and TNF-α (K) by ELISA. (L) In another experiment, acute colitis was induced by oral administration of 3% DSS with drinking water ad libitum for 7 consecutive days. When mice were on DSS, PPE2-peptide was given intraperitoneally while MSZ was given intragastrically alone or in combination on day 3, day 5, day 7, and day 9. Mice from healthy control group was given normal drinking water. After treatment, mice from all the groups were left for 30 days to observe the probability of survival. Data are presented as mean ± SEM of five mice per group for all experiments. Statistical analysis for B and C was performed using two-way repeated-measures ANOVA. Statistical analysis for E–K was performed using an unpaired two-tailed Student’s t test. Survival analysis for L was conducted using the log rank (Mantel-Cox) test. Discussion IBD, particularly UC, remains a challenging chronic inflammatory disorder with limited therapeutic options for refractory cases. Current treatments, including aminosalicylates, corticosteroids, immunomodulators, and biologics, often fail to induce sustained remission of IBD symptom due to mechanistic escape, loss of response, or significant side effects.35 Our study introduces a potential therapeutic approach by targeting mast cells (MCs), which play a pivotal role in gut inflammation, barrier dysfunction, and fibrosis.3,6 We have demonstrated that a synthetic peptide derived from the mycobacterial protein PPE2 (PPE2-peptide) effectively attenuates DSS-induced colitis by selectively depleting mast cells and suppressing their inflammatory mediators through the inhibition of fibroblast-derived SCF. This study highlights an important role of mast cells in colitis pathology as hinted in previous reports2,3,43 and represents a potential strategy to manage inflammation of UC by using PPE2-peptide that significantly reduces mast cell infiltration and activation in the inflamed colon. However, additional effects exerted by the PPE2-peptide on other inflammatory mediators cannot be overlooked, which remain to be explored in future studies. The PPE2-peptide-treated colitis mice exhibited marked improvements in body weight, DAI, and colon, whereas no such improvement was observed in the scrambled peptide-treated group, indicating that the protective effect against colitis is specific to the PPE2-peptide. Also, PPE2-peptide treatment improved intestinal barrier integrity, as evidenced by reduced permeability measured using the FITC-dextran tracer assay. PPE2-peptide treatment of colitis mice reduced the levels of pro-inflammatory cytokines (IL-1β, IL-6, TNF-α) and neutrophil infiltration (MPO activity) in colon tissue compared to untreated colitis mice. Importantly, PPE2-peptide treatment reduced the abdominal visceral pain compared to the untreated colitis group. Since intestinal inflammation is known to contribute to visceral abdominal pain in colitis by promoting inflammation and sensitizing nociceptive pathways (neural pain pathway),44 the attenuation of inflammation by PPE2-peptide treatment may explain the reduced AWR scores observed upon colorectal distension in the peptide-treated group. DSS administration is well known to downregulate the expression of tight junction proteins such as ZO-1, claudin-1, and occludin in mice with colitis.45 Notably, treatment with PPE2-peptide significantly restored the expression levels of these tight junction proteins. PPE2-peptide treatment effectively preserved colonic architecture, which was severely disrupted in the untreated colitis group. Irrespective of the mouse strain (C57BL/6 or BALB/c) or the route of administration (intraperitoneal or intravenous), PPE2-peptide exhibited a similar protective effect against DSS-induced colitis. Interestingly, toluidine blue staining of colon sections across all groups, along with flow cytometry analysis, demonstrated a marked increase in mast cell infiltration in the colonic tissue of untreated colitis mice. This elevated mast cell population was significantly reduced upon PPE2-peptide treatment. Adoptive transfer of bone marrow-derived mast cells (BMMCs) reversed the protective effects of the peptide, as indicated by reduction in body weight, increased DAI score, colon shortening, and elevated levels of pro-inflammatory cytokines (IL-1β, IL-6, and TNF-α). These studies suggest that mast cells are probably one of the important factors of IBD pathology, and mast cell depletion by PPE2-peptide is likely to be central to its therapeutic mechanism. An immunofluorescence study showed the presence of PPE2-peptide in colon tissue upon intraperitoneal administration. Immunofluorescence and in vitro studies further confirmed that the peptide localizes to fibroblast nuclei and inhibits SCF promoter activity. This is consistent with the earlier work showing that recombinantly purified full-length PPE2 protein binds to the SCF promoter via its leucine zipper domain.10 Given that fibroblasts are the primary source of SCF, this mechanism explains the observed mast cell depletion in vivo. Unlike direct mast cell inhibitors (e.g., cromolyn or ketotifen), which block degranulation but do not reduce mast cell numbers, the PPE2-peptide uniquely suppresses mast cell number and survival by disrupting the SCF/c-Kit axis. This is particularly relevant in IBD, where persistent mast cell activation contributes to chronic inflammation and tissue remodeling.12 These findings align with previous reports that SCF is crucial for mast cell recruitment to the injury site and survival,11 and thus its inhibition represents a potential strategy to mitigate mast cell-driven IBD pathology. We showed that the scrambled peptide, despite entering the nucleus due to the intact NLS region, failed to suppress SCF expression or promoter activity, hence being inefficient in attenuating DSS-induced colitis pathology in mice. These observations confirm that the DNA-binding sequence of the PPE2 peptide is essential for its specific transcriptional repression of SCF and its therapeutic effect. Importantly, the peptide exhibited no cytotoxicity or off-target effects on hepatic or renal function, as revealed by no change in the level of AST, ALT, ALP, creatinine, BUN, blood urea, albumin, and total protein. This supports the potential of PPE2-peptide as a safe therapeutic candidate. Mesalazine (5-aminosalicylic acid, 5-Aminosalicylic acid [ASA]), a first-line UC treatment, acts by the local suppression of inflammation by inhibiting cyclooxygenase and lipoxygenase pathways, thereby reducing the production of pro-inflammatory prostaglandins and leukotrienes. Importantly, mesalazine suppresses NF-κB activation, which leads to reduced transcription of multiple pro-inflammatory genes.37 Prolonged or high-dose MSZ use can cause kidney and liver toxicity, blood disorders, and male infertility.37,39 Given the multifactorial nature of IBD, monotherapies often provide incomplete relief. Thus, the combination of the PPE2-peptide with MSZ was explored to determine whether targeting dual pathways could enhance therapeutic efficacy. Compared to the MSZ or PPE2-peptide monotherapy, the combination of MSZ at 50 mg/kg with PPE2-peptide improved clinical parameters and reduced inflammation, including greater suppression of MPO activity, mast cell mediators (β-hexosaminidase, histamine) and pro-inflammatory cytokines. This suggests that combining mast cell-targeted therapy with conventional anti-inflammatory drugs may offer a more comprehensive treatment strategy, particularly for patients with refractory disease. These findings highlight the translational potential of targeting the fibroblast-mast cell axis in IBD. Future studies need to be directed to investigate its efficacy in chronic colitis models and explore its potential in human patients with IBD. Additionally, given the role of SCF in fibrosis, this peptide may also hold promise for preventing stricturing complications in Crohn’s disease. In summary, PPE2-peptide was identified as a mast cell-depleting agent that ameliorates colitis by suppressing fibroblast-derived SCF and could be one of the emerging treatment strategies to control UC. Its efficacy, combined with a safety profile and synergistic potential with existing therapies, positions it as a promising candidate for IBD treatment. As a small synthetic molecule, the peptide offers several therapeutic advantages as it is easier to synthesize and modify, can achieve high tissue specificity due to its targeted mechanism of action, and has a relatively short half-life, which may reduce the risk of long-term systemic toxicity. These properties make it well-suited for localized and transient intervention, particularly in inflamed tissues such as the colon. While oral administration is generally considered safer and more patient-friendly for the treatment of UC, delivering therapeutic peptides via oral route poses challenges due to their susceptibility to enzymatic degradation in the stomach. To overcome this limitation, the PPE2-peptide can be encapsulated using pH-sensitive drug delivery systems designed to protect it from gastric digestion and enable targeted release in the colon, thereby enhancing therapeutic efficacy. Further preclinical and clinical studies are warranted to validate its therapeutic potential in human disease. Limitations of the study In the present study, using a BMMC adoptive transfer approach, we demonstrated that the PPE2-peptide attenuates colonic inflammation in DSS-induced colitis by modulating mast cell-mediated inflammatory responses at the site of inflammation. However, direct validation using mast cell-deficient mouse models would further strengthen the mechanistic understanding of the observed therapeutic effects. In addition, although our findings support mast cell inhibition as a key mechanism underlying the protective effect of the PPE2-derived peptide, it may also modulate additional cellular and molecular pathways, which warrants further investigation. Furthermore, the efficacy of the PPE2-derived peptide was evaluated solely in the DSS-induced colitis model; therefore, assessments in alternative experimental models, such as Trinitrobenzenesulfonic Acid (TNBS)-induced colitis, are needed to establish its broader applicability across distinct inflammatory settings. Another limitation of this study is that all experiments were performed in male mice, and therefore potential sex-dependent differences in colitis disease progression and therapeutic response were not assessed. Additionally, future studies are needed to investigate the therapeutic efficacy of the PPE2-peptide in combination with currently available therapies for colitis, beyond MSZ, including immunomodulators, anti-TNF-α biologics, anti-integrin therapies, or JAK inhibitors, to evaluate potential synergistic or additive therapeutic benefits. Resource availability Lead contact Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Sangita Mukhopadhyay (sangita@cdfd.org.in). Materials availability This study did not generate any new unique reagents. Data and code availability •All data generated or analyzed during this study are included in the manuscript and supplementary figures. All data generated or analyzed during this study are included in the manuscript and supplementary figures. •This study did not generate any unique datasets or code. This study did not generate any unique datasets or code. •Any additional information on data reported in this work is available from the lead contact upon request. Any additional information on data reported in this work is available from the lead contact upon request. Acknowledgments The authors are thankful to Dr Srikanth Battu and Mr Niteen Pathak for discussion and timely help. We thank Dr. Ravi Pal for kindly providing the pGL3-SCF construct used in this study. The authors gratefully acknowledge the financial support by the Science and Engineering Research Board (SERB), Department of Science and Technology (DST), Government of India (JCB/2021/000035), Council of Scientific and Industrial Research (India) (CSIR), Government of India (37WS(0020)/2023-24/EMR-II/ASPIRE), Indian Council of Medical Research (ICMR), Government of India (IIRPSG-2024-01-01453), and a core grant from CDFD by DBT. PK was supported by a fellowship from the Department of Biotechnology (DBT), Government of India. Author contributions P.K. and S.M. conceived, designed the experiments, analyzed the data, and wrote the manuscript. P.K. performed all the experiments. S.M. supervised, corrected and edited the manuscript, finalized the figures and tables, and provided the funds. Declaration of interests The authors declare no competing interests. Declaration of generative AI and AI-assisted technologies in the writing process During the preparation of this work, the authors used ChatGPT (OpenAI) in order to rephrase some portions of the manuscript text to improve readability. After using this tool, the authors reviewed and edited the content as needed and take full responsibility for the content of the published article. STAR★Methods Key resources table REAGENT or RESOURCESOURCEIDENTIFIERAntibodiesAPC anti-mouse CD117 (c-kit) AntibodyBioLegendCat# 135107; RRID:AB_2028405FITC anti-mouse FcεR1α AntibodyBioLegendCat# 134305; RRID:AB_1626102Anti-GFP, N-terminal antibody produced in rabbitSigma-AldrichCat# G1544; RRID:AB_439690β-Actin (C4)Santa Cruz BiotechnologyCat# sc-47778; RRID:AB_626632Chemicals, peptides, and recombinant proteinsDMEM high glucose with sodium pyruvate, without L-glutamineHyCloneCat# SH30285.01RPMI 1640 liquid medium without L-glutamineHyCloneCat# SH30096l.1Fetal Bovine Serum, qualified, BrazilGibcoCat# 10270-106GlutaMAX™ SupplementGibcoCat# 35050061Gibco™ Antibiotic-Antimycotic (100X)GibcoCat#15240-062Dextran sulphate sodium saltMP BiomedicalsCat# 160110Fluorescein isothiocyanate-dextranSigma-AldrichCat# FD4o-Dianisidine dihydrochlorideSigma-AldrichCat# D3252Myeloperoxidase from human leukocytesSigma-AldrichCat# M6908-5Up-Nitrophenyl-N-acetyl-β-D-glucosaminideSigma-AldrichCat# 487052Toluidine Blue OSigma-AldrichCat# 198161TRI ReagentSigma-AldrichCat# T9424iScript™ cDNA Synthesis KitBio-RadCat# 1708891TB Green® Premix Ex Taq™ (Tli RNase H Plus)TakaraCat# RR420ALipofectamine™ 2000 Transfection ReagentInvitrogenCat# 11668-027VECTASHIELD Antifade Mounting Medium with DAPIVector LabsCat# H-1200LiberaseTM Research GradeRocheCat# 05401119001Lipopolysaccharide (LPS)Sigma-AldrichCat# L2630MesalamineSigma-AldrichCat# PHR1060PPE2-peptideGL BiochemN/AScrambled peptideGL BiochemN/AMouse SCF Recombinant ProteinPeprotechCat# 250-03Mouse IL-3 Recombinant ProteinPeprotechCat# 213-13Critical commercial assaysMicro BCATM Protein Assay kitThermo Fisher ScientificCat# 23235Mouse IL-1 beta Uncoated ELISA KitInvitrogenCat# 88-7013Mouse IL-6 Uncoated ELISA KitInvitrogenCat# 88-7064-88Mouse IL-10 Uncoated ELISA KitInvitrogenCat# 88-7105Mouse IL-18 beta Uncoated ELISA KitInvitrogenCat# 88-50618-88Mouse TNF alpha Uncoated ELISA KitInvitrogenCat# 88-7324Mouse IFNg Uncoated ELISA KitInvitrogenCat# 88-7314-88Histamine ELISA kitEnzo Life SciencesCat# ENZ-KIT140A-0001Luciferase assay system with reporter lysis bufferPromegaCat# E4030Experimental models: Cell linesRBL-2H3Kind gift from Dr. Rashna Bhandari, CDFD, Hyderabad, IndiaN/ANIH-3T3ATCCCRL-1658Experimental models: Organisms/strainsC57BL/6 Mice (Male/Female)CDFD Animal house facilityN/ABALB/c Mice (Male/Female)CDFD Animal house facilityN/AOligonucleotidesPrimers for Real-time PCR, see Table S3This paperN/ARecombinant DNApEGFP-C1 vectorClontechCat# V012024pGL3 basic vectorPromegaCat# E1751pGL3-SCF plasmidPal et al.10N/ASoftware and algorithmsPrism 8.4.2GraphPadN/AImageJOpen SourceN/ABioRender: Scientific Figure and Illustration SoftwareBioRenderN/AOtherFogarty 4F embolectomy catheterMadoredCat# EM0480 Experimental model and study participant details Animals Male C57BL/6 and BALB/c mice (6–8 weeks old) were breed and maintained in the animal house facility of BRIC-CDFD, Hyderabad. Animals were housed under specific pathogen-free (SPF) conditions at a temperature of 22 ± 2°C with a 12 hours light/dark cycle and provided ad libitum access to food and water. All animal experiments were approved by the Institutional Animal Ethics Committee (IAEC) of CDFD under approval number [CDFD/16/012]. All procedures were performed in accordance with the guidelines of the Committee for the Purpose of Control and Supervision of Experiments on Animals (CPCSEA), Government of India. Cell lines The rat basophilic leukemia cell line RBL-2H3 (ATCC) was kindly provided by Dr. Rashna Bhandari (BRIC-Centre for DNA Fingerprinting and Diagnostics, Hyderabad, India) and cultured in DMEM (HyClone, USA) supplemented with 15% heat-inactivated fetal bovine albumin (FBS) (Gibco, USA), 1X Glutamax (Gibco, USA) and 1X Anti-Anti (Gibco, USA). The mouse embryonic fibroblast cell line NIH-3T3 was obtained from ATCC and maintained in DMEM supplemented with 10% heat-inactivated FBS, 1X Glutamax and 1X Anti-Anti. Both the cell lines were culture at 37°C in a humidified atmosphere containing 5% CO2. Internal authentication for both the cell lines was not performed because they had already been authenticated by ATCC. Both cell lines were confirmed to be mycoplasma-free before use. Method details Establishment of dextran sodium sulfphate (DSS)-induced acute colitis mice model Acute colitis mice model was established by oral administration of 3% (w/v) DSS (Molecular weight 36,000–50,000, MP Biomedicals, USA) in drinking water for seven days and then replaced it by normal drinking water. From day 3 of DSS administration, mice received intraperitoneal injection of 8 mg/kg of either PPE2-derived synthetic peptide (peptide) or scrambled peptide four times at alternate days. The synthetic PPE2-peptide (KTLLEQTLALLPAALPLLAAPLAPLTLRRRRPKIKQ) and scrambled peptide (AETTPPALLPLLAQLLPAALAKLLLTLRRRRPKIKQ) were purchased from GL Biochem, China and was mass spectrometer validated and HPLC purified with >90% purity. In some experiments, DSS-induced colitis mice were treated with the combination of PPE2-peptide (intraperitoneally) and mesalazine (intragastrically). Mice were either sacrificed at day 9 and were used for various assays or left undisturbed to record survival. Evaluation of clinical symptoms During the course of the experiment, a disease activity index (DAI) score was used to assess the severity of DSS-induced colitis in mice. Various clinical pathologies pertaining to DSS-induced colitis was examined by monitoring the mice for percentage body weight loss, stool consistency and rectal bleeding on a daily basis (Table S1). Each parameter was assigned a score (0–4) based on their severity. Then DAI was calculated by taking average of these three scores. Evaluation of visceral sensitivity by abdominal withdrawal reflex (AWR) Visceral sensitivity was evaluated by measuring the abdominal withdrawal reflex (AWR) in response to colorectal distension (CRD) as described earlier.46 Briefly, mice were anesthetized with 2% isoflurane, and a lubricated balloon catheter (Fogarty 4F, embolectomy catheter, Madored, India) was inserted into the rectum and secured to the tail. After a 30-minute recovery, CRD was applied at graded volumes (50 μL, 100 μL, 150 μL and 200 μL) in conscious animals. AWR responses were scored in a blinded manner on a scale of 0–4 based on behavioral changes: no response (0); immobility with occasional head clenching at stimulus onset (1); mild abdominal muscle contraction without abdominal lifting (2); strong contraction with abdominal lifting (3); body arching with elevation of pelvic structures and scrotum (4) with a 3-minute interval between distensions. Intestinal permeability test Intestinal permeability was measured as described elsewhere.47 In brief, on the day of sacrifice, mice were deprived of food for 4 hours. Fluorescein isothiocyanate (FITC)-dextran (3–5 kDa, Sigma-Aldrich, USA) in 100 μL PBS was given intragastrically as per 0.6 mg/kg body weight. After 3 hours of FITC-dextran administration, mice were bled and hemolysis-free serum was collected. Standard curve for FITC-dextran were prepared by serially diluting FITC-dextran in mouse serum. Fluorescence intensity of diluted serum was measured at excitation 488 nm and emission 520 nm. Myeloperoxidase (MPO) assay Myeloperoxidase (MPO) assay was carried out as described earlier.48 Colon tissue lysates were prepared by homogenizing mice colon in 50 mM phosphate buffer (pH, 6.0) containing 0.5% cetyltrimethylammonium bromide (CTAB). Then colon tissue lysates were incubated with 50 mM phosphate buffer containing 30 mM o-dianisidine dihydrochloride (Sigma-Aldrich, USA) and 0.005% H2O2 (Sigma-Aldrich, USA) at 37°C for 20 minutes, and absorbance was recorded at 460 nm. Standard curve for MPO assay was prepared by serially diluting human leukocyte MPO (Sigma-Aldrich, USA) in 50 mM PBS. β-hexosaminidase assay β-hexosaminidase activity was measured in colon tissue lysate as described elsewhere.49 In brief, colon tissue lysates were prepared in 50 mM phosphate buffer with 1% Triton X-100 by mechanical homogenizer. Equal amounts of colon tissue lysates were incubated with 0.04 M citrate buffer (pH, 4.5) containing 10 mM p-nitrophenyl N-acetyl-α-d-glucosaminide (Sigma-Aldrich, USA) at 37°C for 60 minutes. The reaction was terminated by the addition of 0.2 M Glycine buffer (pH, 10.7), and absorbance was recorded at 405 nm. Histopathology Mice were sacrificed, and colon tissues were collected for all the groups and were fixed in 10% neutral buffered formalin. Tissue samples were embedded in paraffin wax and sectioned (5 μm) for further staining. For hematoxylin and eosin (H&E) staining, the sections were deparaffinized in xylene and then rehydrated by passing them through graded alcohols (100%, 95%, 67%) and finally hydrated in distilled water. Next, sections were stained with hematoxylin, washed in distilled water, and counterstained with eosin (1% in distilled water). Sections were washed, dehydrated, and mounted on the slides using mounting medium for imaging. Histomorphological evaluation of the colon was performed as mentioned elsewhere.50 In brief, histopathological severity of tissue damage was scored in a blinded fashion. The extent of inflammatory cell infiltration (score 1) in colon tissue and colon architecture (score 2) was graded as mentioned in Table S2. The sum of the score 1 and score 2 was used to represent the histopathological score. For toluidine blue staining, the sections were deparaffinized in xylene followed by hydration in distilled water. Further, the sections were stained in the toluidine blue solution [0.5% toluidine blue in 1% NaCl (pH, 2.3)] for 2 to 3 minutes. Slides were washed with distilled water, dehydrated using 100% ethanol, and mounted on the slides for image acquisition. Tissue section images were acquired using Nikon ECLIPSE Ti2 light upright microscope. Quantification of cytokines and histamine by ELISA Levels of IL-1β, TNF-α and IL-6 cytokines in colon tissue lysates were quantified by sandwich ELISA following the manufacturer’s protocol (Thermo Fisher Scientific, USA). The levels of histamine in colon tissue lysates were estimated by Histamine ELISA kit following the manufacturer’s protocol (Enzo Life Sciences, USA). Absolute concentrations of IL-1β/TNF-α/IL-6 cytokine or histamine were measured using a standard curve provided by the manufacturer respectively. RNA isolation, cDNA synthesis and real-time PCR For RNA isolation, NIH-3T3 cells or colon tissues were homogenized in TRI Reagent (Sigma-Aldrich, USA), and chloroform was added. The samples were centrifuged for 20 minutes at 12000 g at 4°C, and the transparent supernatant was collected. An equal amount of isopropanol was added, and the mixture was centrifuged for 10 minutes at 12000 g (4°C). The pellets were washed once with 75% ethanol at 7500 g (4°C) for 5 minutes. After air-drying, the pellet was dissolved in nuclease-free water, and total RNA was subsequently purified by lithium chloride precipitation, as described elsewhere.51 The RNA quantity and quality were analyzed by NanoDrop (Thermo Fisher Scientific, USA). The cDNA synthesis was carried out using iScript cDNA Synthesis Kit as per the manufacturer’s protocol (Bio-Rad, USA). Real-time PCR was carried out with specific set of primers (Table S3) using Applied Biosystems QuantStudio 5 Real-Time PCR System (Thermo Fisher Scientific, USA) with TB Green Premix Ex Taq (Tli RNaseH Plus) (Takara, Japan) for detection. A comparative Ct method (2-ΔΔCt) was used to calculate the relative change in mRNA levels using expression from untreated control as base (one-fold) as described elsewhere.52 Briefly, ΔCt is the Ct value for the gene of interest normalized to the Ct value of the respective internal control, β-actin for NIH-3T3 cell-line and Rps29 for colon tissue. ΔΔCt values were calculated as a relative change in ΔCt of the target gene in all the groups with respect to healthy control. Fold changes in the mRNA levels were expressed as 2-ΔΔCt. Cell isolation from colon tissue and analysis of mast cells by fluorescence-activated cell sorting (FACS) Single-cell suspensions from colon tissues were prepared as described earlier.53 Briefly, colon tissues were harvested in PBS supplemented with 0.1% BSA, cleaned, and incubated in RPMI-1640 supplemented with 10% FBS and 2 mM EDTA on shaking incubator (150 rpm) at 37°C for 20 minutes, followed by incubation in RPMI-1640 supplemented with 10% FBS for 10 minutes, without shaking. Tissues were then incubated in 1 mL of RPMI-1640 supplemented with Liberase (0.5 U/ml, Roche, Germany) and DNase I (0.1 mg/mL, Thermo Fisher Scientific, USA), Ca2+ and Mg2+ at 37°C for 90 minutes at shaking incubator (150 rpm). Next digested soft tissues were filtered through 70 μm strainer to obtain single cell suspension. For flow cytometry analysis, cells were washed with PBS and stained with anti-CD117 antibody (Ab) conjugated to APC (Biolegend, USA, 0.5 μg/106 cells) and anti-FcεRI Ab conjugated to FITC (Biolegend, USA, 0.25 μg/106 cells) diluted in staining buffer (1% BSA [bovine serum albumin] in 1X PBS containing 0.01% sodium azide) for 1 hour on ice. Cells were next analyzed by flow cytometry (BD LSR Fortessa; BD Biosciences, USA). Bone marrow-derived mast cell (BMMC) culture Mast cells were isolated form C57BL/6 mice of 6–8 weeks of age as described elsewhere.54 In brief, mice were sacrificed by CO2 asphyxiation and femur bones were collected under aseptic conditions. Next culture medium [RPMI-1640 (HyClone, USA) supplemented with 10% FBS (Gibco, USA), 1X Glutamax (Gibco, USA) and 1X Anti-Anti (Gibco, USA)] was used to flush the bones using a syringe to isolate bone marrow cells. Next, cells were centrifuged at 1200 rpm for 5 minutes at 4°C, supernatant was discarded and cell pellet was resuspended in culture medium supplemented with SCF (30 ng/mL, Peprotech, USA) and IL-3 (20 ng/mL, Peprotech, USA) for 25 days. The purity of BMMC population was checked by flow cytometry using anti-CD117 Ab and anti-FcεRI Ab. Adoptive transfer of BMMCs in mice Three days after DSS administration, C57BL/6 mice were administered intraperitoneally with PPE2-peptide for four times, on day 3, day 5, day 7 and day 9 and about 1 × 106 cultured BMMCs were administered intraperitoneally at day 5 and day 7. At day 9, mice were sacrificed and all the pathophysiological parameters were assessed. Confocal microscopy To study localization of PPE2-peptide in colon tissue, mice were intraperitoneally injected with PPE2-peptide and after 1.5 hours mice were sacrificed and colon tissues were harvested and tissue sections were made. Next, the sections were incubated with anti-PPE2 Ab (in house raised in rabbit, 1:200) for overnight at 4°C. After washing, sections were incubated with Alexa Fluor 488-conjugated goat anti-rabbit Ab (Thermo Fisher Scientific, USA) at 1:500 dilution for 60 minutes at room temperature. Next, sections were washed and mounted in VECTASHIELD Antifade Mounting Medium containing DAPI (Vector labs, USA). Images were acquired using Leica SP-8 confocal microscope. Also, NIH-3T3 cells were treated with either PBS or PPE2-peptide (500 nM) and after 2 hours cells were washed with 1X PBS followed by fixation with 4% paraformaldehyde (PFA). Next, cells were incubated with anti-PPE2 Ab for overnight at 4°C followed by Alexa Fluor 488–conjugated anti-rabbit secondary Ab for 1 hour. Cells were next washed and mounted in VECTASHIELD Antifade Mounting Medium containing DAPI (Vector labs, USA) and observed under Leica SP-8 confocal microscope. Transfection and luciferase assay To study the promoter activity, pGL3 vector containing putative SCF promoter were transiently co-transfected with pEGFP plasmid into NIH-3T3 fibroblast cell line using Lipofectamine 2000 (Invitrogen, USA) following the manufacturer’s protocol.10 After 5 hours of transfection, medium was replaced by fresh complete DMEM medium containing 10% FBS. After 24 hours, transfection efficiency was confirmed by visualizing the cells under fluorescence microscope (Nikon ECLIPSE Ti2) for the expression of GFP. Next, cells were treated with PPE2-peptide for 3 hours. The promoter activity in the presence and absence of PPE2-peptide was checked using Luciferase kit as per the manufacture’s protocol (Promega, USA). Quantification and statistical analysis Statistical analyses were performed using GraphPad Prism software, version 8.4.2. Data are presented as mean ± SEM. Time-course data were analyzed using two-way repeated-measures ANOVA. Comparisons between two groups were performed using an unpaired two-tailed Student’s t-test. Survival curves were analyzed using the log-rank (Mantel-Cox) test. p < 0.05 was considered to be significant. Footnotes Supplemental information can be found online at https://doi.org/10.1016/j.isci.2026.116792. Supplemental information Document S1. Figures S1–S6 and Tables S1–S3 References Associated Data Supplementary Materials Document S1. Figures S1–S6 and Tables S1–S3 Data Availability Statement •All data generated or analyzed during this study are included in the manuscript and supplementary figures. All data generated or analyzed during this study are included in the manuscript and supplementary figures. •This study did not generate any unique datasets or code. This study did not generate any unique datasets or code. •Any additional information on data reported in this work is available from the lead contact upon request. Any additional information on data reported in this work is available from the lead contact upon request.